8-K: DarioHealth Corp. Faces Nasdaq Delisting Risk After Share Price Falls Below $1

DarioHealth Corp. has received a notice from Nasdaq for non-compliance with the minimum bid price rule, as its stock price has remained below $1 for 30 consecutive business days.

Summary

• DarioHealth Corp. received a notice from Nasdaq on September 16, 2024, stating that it is not compliant with Nasdaq Listing Rule 5550(a)(2).
• The company's stock price has been below $1.00 per share for 30 consecutive business days.
• DarioHealth has been granted a 180-day compliance period, until March 17, 2025, to regain compliance.
• To regain compliance, the stock price must close at or above $1.00 for at least 10 consecutive business days.
• If compliance is not achieved by March 17, 2025, a second 180-day compliance period may be granted if certain conditions are met.
• Failure to regain compliance within the allotted time may result in delisting from Nasdaq.
• The company intends to monitor its stock price and consider options to resolve the noncompliance.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (potential delisting) and uncertainty about the company's ability to recover. The sentiment is negative due to the risk of delisting and the lack of a clear path to compliance.

Positives

• DarioHealth has been granted a 180-day period to regain compliance with Nasdaq's minimum bid price rule.
• The company may be eligible for a second 180-day compliance period if it meets certain conditions.

Negatives

• DarioHealth's stock price has fallen below $1.00 for 30 consecutive business days, triggering a non-compliance notice from Nasdaq.
• There is no assurance that the company will be able to regain compliance with the minimum bid price requirement.
• Failure to regain compliance could result in the company's stock being delisted from Nasdaq.

Risks

• The company faces the risk of delisting from Nasdaq if it cannot raise its stock price above $1.00 for at least 10 consecutive business days by March 17, 2025.
• There is no guarantee that the company will be able to meet the requirements for a second compliance period.
• The company's stock price may be volatile due to the uncertainty surrounding its compliance status.

Future Outlook

The company intends to monitor its stock price and consider available options to resolve the noncompliance, but there is no assurance of success.

Management Comments

• The company intends to monitor the closing bid price of its common stock between now and March 17, 2025.
• The company will consider available options to resolve the Companys noncompliance with the minimum bid price requirement as may be necessary.

Industry Context

This announcement highlights the challenges faced by companies with low stock prices, particularly in maintaining their listing on major exchanges like Nasdaq. It is not uncommon for companies to receive delisting notices when their stock price falls below the minimum threshold.

Comparison to Industry Standards

• Many companies listed on Nasdaq are required to maintain a minimum bid price of $1.00 per share to remain listed.
• Companies that fail to meet this requirement are often given a grace period to regain compliance, similar to the 180-day period granted to DarioHealth.
• Other companies that have faced similar delisting notices include [hypothetical company A] and [hypothetical company B], which had to implement reverse stock splits or other measures to regain compliance.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted from Nasdaq.
• Employees may experience uncertainty about the company's future.
• The company's reputation may be negatively impacted by the delisting notice.

Next Steps

• The company will monitor its stock price between now and March 17, 2025.
• The company will consider available options to resolve the noncompliance with the minimum bid price requirement.

Key Dates

Keywords

Nasdaq, delisting, compliance, minimum bid price, stock price, DarioHealth, DRIO